Background:
Circulating endothelial progenitor cells (EPCs) have regenerative capacities
and play an important role in vessel wall homeostasis. When attracted to the site of vessel wall
injury, EPCs rapidly differentiate into a functional layer as part of the healing process. The Genous
TM endothelial progenitor cell (EPC) capturing stent is coated with anti-human CD34+ antibodies
which combine with circulating EPCs from the peripheral blood to the stent surface.
Objective:
This meta-analysis aims to explore the Genous TM endothelial progenitor cell capturing
stent in coronary artery disease (CAD) adverse event rate after one-year follow-up.
Methods:
PubMed, EMBASE and, Google Scholar databases were searched for eligible studies.
CAD survival data and clinicopathological features were analyzed by expected shortfall (ES) and
95% CI. Fixed-effect model and random-effect model are used for summary statistics.
Results:
12 studies, including 15985 coronary artery disease (CAD) patients who received PCI
treatment were included in this study. After 1-year follow-up, the rate of adverse event showed that
the target vessel failure (TVF) was 8.5% (7.6%-17.4%), target vessel revascularization was 4.1%
(TVR, 0-15.6%), target lesion revascularization was 4.2% (TLR, 3.7%-22%), myocardial infarction
was 2.0% (MI, 1.8%-5.2%), major adverse cardiac events was 8.7% (MACE, 6.4%-28%), and the
all-cause death was 4.0% (0-9.2).
Conclusion:
After one-year follow-up, the incidence rate of Genous stent adverse events was stable
in CAD patients. The study showed a better evaluation of Genous stent, and it provides a better
reference for CAD clinical treatment.
The analysis of the lipid levels in patients with coronary artery disease after percutaneous coronary intervention: a one-year follow-up observational study
